Mangoceuticals, Inc. (MGRX)
NASDAQ: MGRX · Real-Time Price · USD
2.650
+0.150 (6.00%)
Nov 22, 2024, 4:00 PM EST - Market closed
Mangoceuticals Revenue
Mangoceuticals had revenue of $133.37K in the quarter ending September 30, 2024, a decrease of -45.60%. This brings the company's revenue in the last twelve months to $755.00K, up 52.20% year-over-year. In the year 2023, Mangoceuticals had annual revenue of $731.49K with 8,083.16% growth.
Revenue (ttm)
$755.00K
Revenue Growth
+52.20%
P/S Ratio
5.79
Revenue / Employee
$251,667
Employees
3
Market Cap
6.27M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 731.49K | 722.55K | 8,083.16% |
Dec 31, 2022 | 8.94K | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMGRX News
- 4 weeks ago - MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly - GlobeNewsWire
- 5 weeks ago - Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024 - Newsfile Corp
- 5 weeks ago - Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter - Benzinga
- 6 weeks ago - MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN - GlobeNewsWire
- 7 weeks ago - MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions - GlobeNewsWire
- 7 weeks ago - MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment - GlobeNewsWire
- 3 months ago - MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024 - GlobeNewsWire
- 3 months ago - MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide - GlobeNewsWire